is increased among patients with motor neuron disease, during
first years after stroke, after diagnosing
LATYPOVA, G.M.,
BYCHENKOVA, M.A.,
KATAYEV, V.A.,
PERFILOVA, V.N.,
TYURENKOV, I.N.,
MOKROUSOV, I.S.,
PROKOFIEV, I.I.,
SALIKHOV, SH.M.,
IKSANOVA, G.R. (2019) for the
first time. We showed that the PVSHE has a cardioprotective effect when it was administered at a dose
TUGUZBAEVA, G.,
YUE, E.,
CHEN, X.,
HE, L.,
LI, X.,
JU, J.,
QIN, Y.,
PAVLOV, V.,
LU, Y.,
JIA, W.,
BAI, Y.,
NIU, Y.,
YANG, B (2019) -dissociating therapeutic agent in vitro.
Firstly, we found marked enrichment of αv integrin in collectively invading
Wang, J.,
Fang, R.,
Wang, L.,
Chen, G.,
Wang, H.,
Wang, Z.,
Zhao, D.,
Pavlov, V.N.,
Kabirov, I.,
Wang, Z.,
Guo, P.,
Peng, L.,
Xu, W. (2018) performance and significance of CAIX as an imaging agent. Methods: We
first analyzed the data from The Cancer
ATAS, A.E.,
SARAC, A.,
DIRICAN, A.,
TOPBASI, N.,
UZAR, T.,
RASTGAR, L.,
PANKINA, E.,
OZKAYA, S. (2019) died in
first 24 hours after thrombolysis. Conclusions: We concluded that the risk
factors, ECG
Romanov, G.P.,
Pshennikova, V.G.,
Lashin, S.A.,
Solovyev, A.V.,
Teryutin, F.M.,
Cherdonova, A.M.,
Borisova, T.V.,
Sazonov, N.N.,
Khusnutdinova, E.K.,
Posukh, O.L.,
Fedorova, S.A.,
Barashkov, N.A. (2020) . For the
first time, we analyzed the data on the distribution of SL users that became available for the total